AstraZeneca Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

AstraZeneca wird ein jährliches Gewinn- und Umsatzwachstum von 18.4% bzw. 6.3% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 19.3% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 28.8% betragen.

Wichtige Informationen

18.4%

Wachstumsrate der Gewinne

19.3%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	19.5%
Wachstumsrate der Einnahmen	6.3%
Zukünftige Eigenkapitalrendite	28.8%
Analystenabdeckung	Good
Zuletzt aktualisiert	20 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Gewinn- und Umsatzwachstumsprognosen

BASE:AZN - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	60,616	11,680	13,756	16,609	22
12/31/2025	57,208	10,175	11,698	14,928	24
12/31/2024	53,290	8,363	7,084	11,736	22
9/30/2024	51,206	6,495	6,867	11,334	N/A
6/30/2024	49,133	6,440	7,045	11,065	N/A
3/31/2024	47,611	6,331	5,887	9,698	N/A
12/31/2023	45,811	5,955	6,858	10,345	N/A
9/30/2023	44,994	5,896	7,270	10,363	N/A
6/30/2023	44,485	6,163	6,854	10,179	N/A
3/31/2023	43,840	4,705	6,357	9,709	N/A
12/31/2022	44,351	3,288	7,684	9,808	N/A
9/30/2022	45,155	2,040	6,538	8,828	N/A
6/30/2022	44,038	-1,253	5,789	7,617	N/A
3/31/2022	41,487	-1,063	5,721	7,261	N/A
12/31/2021	37,417	112	4,350	5,963	N/A
9/30/2021	32,816	1,471	5,184	6,343	N/A
6/30/2021	29,528	3,771	5,421	6,446	N/A
3/31/2021	27,583	3,977	4,899	6,594	N/A
12/31/2020	26,617	3,196	3,144	4,799	N/A
9/30/2020	25,871	2,497	3,273	4,376	N/A
6/30/2020	25,699	2,148	3,057	3,657	N/A
3/31/2020	25,247	1,522	2,789	3,495	N/A
12/31/2019	24,384	1,335	2,585	2,969	N/A
9/30/2019	24,137	2,056	4,230	3,818	N/A
6/30/2019	23,071	2,188	3,543	3,184	N/A
3/31/2019	22,403	2,408	3,621	2,371	N/A
12/31/2018	22,090	2,155	3,585	2,618	N/A
9/30/2018	21,450	2,422	1,202	1,391	N/A
6/30/2018	22,342	2,677	N/A	3,165	N/A
3/31/2018	22,238	2,804	N/A	3,350	N/A
12/31/2017	22,465	3,001	N/A	3,578	N/A
9/30/2017	22,273	3,542	N/A	4,541	N/A
6/30/2017	21,740	3,870	N/A	3,109	N/A
3/31/2017	22,292	3,390	N/A	3,040	N/A
12/31/2016	23,002	3,499	N/A	4,145	N/A
9/30/2016	23,816	2,465	N/A	2,756	N/A
6/30/2016	24,062	2,221	N/A	3,690	N/A
3/31/2016	24,766	2,921	N/A	4,589	N/A
12/31/2015	24,708	2,825	N/A	3,324	N/A
9/30/2015	25,025	1,696	N/A	4,595	N/A
6/30/2015	25,689	1,180	N/A	4,800	N/A
3/31/2015	26,144	1,279	N/A	5,799	N/A
12/31/2014	26,547	1,233	N/A	7,058	N/A
9/30/2014	26,675	1,030	N/A	7,694	N/A
6/30/2014	26,316	2,022	N/A	6,862	N/A
3/31/2014	25,786	2,049	N/A	6,389	N/A
12/31/2013	25,806	2,556	N/A	7,400	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: AZNDas prognostizierte Gewinnwachstum (18.4% pro Jahr) liegt über der Sparquote (8.7%).

Ertrag vs. Markt: AZNDie Erträge des Unternehmens (18.4% pro Jahr) werden voraussichtlich schneller wachsen als der Markt AR (10.5% pro Jahr).

Hohe Wachstumserträge: AZNDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: AZNDie Einnahmen des Unternehmens (6.3% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt AR (12.1% pro Jahr).

Hohe Wachstumseinnahmen: AZNDie Einnahmen des Unternehmens (6.3% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: AZNDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (28.8%)

AstraZeneca Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

AstraZeneca PLC Revises Earnings Guidance for the Fiscal Year 2024

Recent updates

AstraZeneca PLC Revises Earnings Guidance for the Fiscal Year 2024

Daiichi Sankyo and AstraZeneca Submits New Biologics License Application for Accelerated Approval in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Amgen and AstraZeneca Announce Positive Top-Line Results from the Phase 3 WayPOINT Trial in Patients with Chronic Rhinosinusitis with Nasal Polyps

Daiichi Sankyo and AstraZeneca Announce Three Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer

Astrazeneca plc Announces Astrazeneca and Ionis' Wainzua (Eplontersen) Recommendation for Approval by the Committee for Medicinal Products for Human Use (CHMP) in the European Union

AstraZeneca PLC Announces AIRSUPRA (Albuterol/Budesonide) Demonstrated Statistically Significant and Clinically Meaningful Reduction in the Risk of Severe Exacerbations in Patients with Intermittent or Mild Persistent Asthma in BATURA Phase III Trial

AstraZeneca PLC Announces AIRSUPRA (Albuterol/Budesonide) Demonstrated Statistically Significant and Clinically Meaningful Reduction in the Risk of Severe Exacerbations in Patients with Intermittent or Mild Persistent Asthma in BATURA Phase III Trial

Astrazeneca’S CALQUENCE® (acalabrutinib) Receives Priority Review in the US for Patients with Untreated Mantle Cell Lymphoma

Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Cas Datifan in Combination with Volrustomig in Renal Cell Carcinoma

Astrazeneca and Daiichi Sankyo's Supplemental Biologics License Application for ENHERTU (Fam-Trastuzumab Deruxtecan-nxki) Accepted and Granted Priority Review in the US

Enhertu Grants Daiichi Sankyo and Astrazeneca Priority Review in the U.S. for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Who Have Received At Least One Line of Endocrine Therapy

Astrazeneca PLC Tagrisso Receives US Approval in Unresectable Stage III EGFR-Mutated Lung Cancer Lung Cancer

Datopotamab Deruxtecan Significantly Extended Progression-Free Survival Versus Chemotherapy in Patients with Hr Positive, Her2 Low or Negative Breast Cancer in Patients with Hr Positive, Her2 Low or Negative Breast Cancer

AstraZeneca PLC’s FluMist Receives Approval for Self-Administration in the US

AstraZeneca PLC's Fasenra Approves in the US for Eosinophilic Granulomatosis with Polyangiitis

AstraZeneca Announces Positive Results from the Niagara Phase III Trial

Daiichi Sankyo Company Limited and Astrazeneca Announces Enhertu Showed Substantial Clinical Activity in Patients with Her2 Positive Metastatic Breast Cancer and Brain Metastases

Astrazeneca Presents Interim Results from the Randomized NeoCOAST-2 Phase 2 Study in Early-Stage NSCLC Present At the WCLC 2024

Astrazeneca's Imfinzi Receives Approval in US for the Treatment of Resectable Non-Small Cell Lung Cancer Before and After Surgery

Astrazeneca's Supplemental Biologics License Application for Imfinzi (Durvalumab) Granted Priority Review and Breakthrough Therapy Designation for Patients with Limited-Stage Small Cell Lung Cancer in the US

Astrazeneca Announces Positive High-Level Results from an Interim Analysis of the Amplify Phase III Trial

FDA Advisory Committee Reviewes Astrazeneca's Imfinzi for Treatment of Resectable Non-Small Cell Lung Cancer Based on Aegean Phase III Trial Results

Astrazeneca plc Announces Voydeya Approved in Canada as Add-On Therapy to Ravulizumab or Eculizumab for Adults with the Rare Disease PNH Who Have Residual Hemolytic Anemia Due to Extravascular Hemolysis

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken